Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by HC Wainwright
Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Friday. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 44.40% from the stock’s previous close.
Other equities analysts also recently issued research reports about the stock. Maxim Group set a $14.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Saturday, May 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Tuesday, June 6th. BidaskClub downgraded shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Abeona Therapeutics in a report on Thursday, June 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.86.
Shares of Abeona Therapeutics (NASDAQ:ABEO) remained flat at $13.85 during mid-day trading on Friday. The company’s stock had a trading volume of 606,557 shares. The stock has a 50-day moving average of $9.37 and a 200-day moving average of $6.64. The firm’s market cap is $557.97 million. Abeona Therapeutics has a 12-month low of $4.05 and a 12-month high of $15.25.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.07. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. On average, analysts expect that Abeona Therapeutics will post ($0.67) EPS for the current fiscal year.
WARNING: “Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by HC Wainwright” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/08/abeona-therapeutics-inc-abeo-stock-rating-reaffirmed-by-hc-wainwright.html.
Large investors have recently modified their holdings of the stock. Private Advisor Group LLC increased its holdings in Abeona Therapeutics by 50.0% in the 1st quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 6,999 shares during the period. Family Management Corp acquired a new position in Abeona Therapeutics in the 1st quarter worth approximately $120,000. State of Wisconsin Investment Board acquired a new position in Abeona Therapeutics in the 2nd quarter worth approximately $122,000. Segantii Capital Management Ltd increased its holdings in Abeona Therapeutics by 564.6% in the 1st quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 28,794 shares during the period. Finally, Rhumbline Advisers acquired a new position in Abeona Therapeutics in the 2nd quarter worth approximately $190,000. Institutional investors own 38.24% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.